United Therapeutics

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

United Therapeutics achieves record 2022 performance, eyes revenue doubling

United Therapeutics had a remarkable year in 2022, with strong financial performance and market acceptance of its products. While facing challenges and questions from analysts, UTHR remains focused on growth and innovation.

United Therapeutics reports robust Q1 growth and eyes new opportunities

United Therapeutics (UTHR) showcased strong revenue growth, product performance, and strategic investments in manufacturing facilities and pipeline trials. Challenges include managing factors affecting Tyvaso revenue and patient flow between key products. However, opportunities from new FDA approvals and organ manufacturing advancements position UTHR for continued growth and innovation.

United Therapeutics achieves record revenue, eyes growth beyond hypertension

United Therapeutics delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and strategic product positioning.
The company's focus on combination therapies, expansion into new markets, and commitment to innovation position it well for future success.
Challenges in market saturation and limited drug options in certain therapeutic areas require targeted strategies and continued R&D efforts for sustained growth.
Overall, United Therapeutics' Q2 performance reflects a balance of strengths, challenges, and opportunities that shape its trajectory in the healthcare sector.

United Therapeutics reports record Q3 revenue and growth opportunities

United Therapeutics had a robust Q3 performance with record revenue and growth, driven by strong performance in the Tyvaso franchise. The company is strategically positioned for growth across its commercial business, pipeline programs, and organ technologies. While facing competition and trial challenges, UTHR remains optimistic about its growth potential and opportunities in addressing critical medical needs.

United Therapeutics reports record revenue growth and highlights innovative pipeline

United Therapeutics (UTHR) delivered a strong performance in Q4 2023, showcasing record revenue growth and confidence in its product portfolio. While facing challenges like patient demand fluctuations and potential competition, UTHR remains focused on innovation and growth opportunities in its pipeline.

United Therapeutics reports record revenue and advances in organ manufacturing

United Therapeutics (UTHR) delivered strong financial performance in Q1 2024, driven by revenue growth and strategic capital allocation initiatives.
The company's focus on product innovation, clinical advancements, and organ manufacturing positions UTHR well for future growth and market competitiveness.
While facing challenges in market penetration and product integration, UTHR has opportunities to expand its market presence, enhance treatment options, and pioneer advancements in organ transplantation.

United Therapeutics (UTHR) reports record revenue and strategic growth

United Therapeutics (UTHR) delivered a strong performance in Q2 2024, driven by record revenue and strategic product focus. The company's emphasis on innovation, market competitiveness, and employee satisfaction positions it well for future growth. Challenges in navigating market dynamics and executing key studies require focused attention, while opportunities exist in expanding market share and optimizing capital allocation.

United Therapeutics reports record revenue growth, faces litigation challenges

United Therapeutics delivered a strong performance in Q3 2024, achieving record revenue and significant growth in key product segments.
While facing challenges such as litigation accrual and slower growth in certain product revenues, the company remains well-positioned for future opportunities.
Investors have shown confidence in United Therapeutics, as reflected in the stock appreciation post ASR program, indicating positive market sentiment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Get a deeper insight into the potential performance of United Therapeutics (UTHR) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Unveiling United Therapeutics (UTHR) Q4 Outlook: Wall Street Estimates for Key Metrics

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 21, 2024. United Therapeutics will host a public webcast Wednesday, February 21, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast.

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024

Brainsway

Vertex Pharmaceuticals

From CRISPR gene editing to modify ideal agricultural traits, synthetic biology to promote eco-friendly engineering, or even that relating to biofuels, the field of biotechnology, also known as biotech, offers exciting disruptive solutions with the potential to expand to market caps worth trillions! With new catalysts such as artificial intelligence and quantum computing offering methods to unlock complicated data sets to hasten drug development pipelines, it's no wonder that this market has a projected compound annual growth rate of 13.96% from 2024 to 2023.

Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January

UnitedHealth Group

Healthcare stocks remain a focal point for investors seeking stability and growth. The convergence of technology and an increased emphasis on global health has created an environment for ripe investment opportunities.

3 Must-Buy Healthcare Stocks for a Healthy 2024

Atossa Genetics

Sarepta Therapeutics

For many biotech stocks, price and performance hinges on the success of a drug in testing. This means most biotech companies rely on one market opportunity to succeed financially.

Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company's business during a presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 8, 2024, from 11:15 a.m. to 11:55 a.m., Pacific Standard Time.

United Therapeutics Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Allegro MicroSystems

Calix

Celsius Holdings

Civitas Resources

Darling Ingredients

Frontier Communications Corporation

HealthEquity

Interactive Brokers

Iridium Communications

Jazz Pharmaceuticals

Lantheus Holdings

MP Materials

Matador Resources

Perrigo

R1 RCM Inc

Teradata

TKO Group Holdings Inc

Valaris Ltd

Essential Utilities

When investors think about whether to increase their exposure beyond the big companies that grab most of the headlines in the financial media, they are likely to look at small-cap stocks first. After all, the sky's the limit.

20 midcap stocks with 2024 upside ranging up to 62%, according to analysts

Miromatrix Medical Inc

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. (“Merger Sub”), has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per.

United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. (“Merger Sub”), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon th.

United Therapeutics and Miromatrix Medical Announce Successful Tender Offer

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics (Nasdaq: UTHR), a public benefit corporation, today announced that the company has been named on Newsweek's list of America's Most Responsible Companies 2024. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The list of awards was announced on December 6, 2023, is available on Newsweek's website, and recognizes the top 600 most responsi.

United Therapeutics Named by Newsweek as One of America's Most Responsible Companies 2024

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

United Therapeutics (UTHR) Up 5.2% Since Last Earnings Report: Can It Continue?

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Miromatrix Medical Inc. (NasdaqCM: MIRO) to United Therapeutics Corporation (NasdaqGS: UTHR). Under the terms of the proposed transaction, shareholders of Miromatrix will receive $3.25 in cash for each share of Miromatrix that they own, as well as an additional $1.75 per share in cash upon the achievement of a.

MIROMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Miromatrix Medical Inc. - MIRO

Alkermes

Amphastar Pharma

Ginkgo Bioworks Holdings

DaVita

OraSure Technologies

If you're a fan of the hit TV show Shark Tank, you've probably come across the intriguing term “unicorn” companies. Indeed, these fantastical entities are not only confined to the realm of imagination.

7 Healthcare Stocks That Are Poised to Become the Next Unicorns

United Therapeutics Corporation (NASDAQ:UTHR ) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET Company Participants Dewey Steadman – Head of Investor Relations Martine Rothblatt – Chairperson and Chief Executive Officer Michael Benkowitz – President and Chief Operating Officer James Edgemond – Chief Financial Officer and Treasurer Pat Poisson – Executive Vice President of Technical Operations Leigh Peterson – Senior Vice President of Product Development & Xenotransplantation Conference Call Participants Terence Flynn – Morgan Stanley Hartaj Singh – Oppenheimer Joseph Thome – TD Cowen Eun Yang – Jefferies Jessica Fye – JPMorgan Ash Verma – UBS Operator Good morning, and welcome to the United Therapeutics Corporation Third Quarter 2023 Earnings Webcast. My name is Rocco, and I will be your conference operator today.

United Therapeutics Corporation (UTHR) Q3 2023 Earnings Call Transcript

United Therapeutics (UTHR) third-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2023. Total revenues in the third quarter of 2023 grew 18% year-over-year to $609.4 million, compared to $516.0 million in the third quarter of 2022. “It's a testament to our innovative research and commercial execution that we are again reporting record quarterly revenue and do.

United Therapeutics Corporation Reports Third Quarter 2023 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled in the registration-phase TETON PPF study, which will evaluate nebulized Tyvaso® (treprostinil) Inhalation Solution in 698 adult patients with progressive pulmonary fibrosis (PPF). This is in addition to two separate ongoing registration-phase studies, TETON 1 and TETON 2, of nebulized Tyvaso in pati.

United Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary Fibrosis

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.,--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company's business during a fireside chat session at the UBS Biopharma Conference 2023 in Miami Beach, Florida. The session will take place on Wednesday, November 8, 2023, from 10:00 a.m. to 10:25 a.m., Eastern Standard Tim.

United Therapeutics Corporation to Present at the UBS Biopharma Conference 2023

Shares in the artificial human organs specialist Miromatrix Medical Inc. jumped 25% in premarket trading following the announcement of its acquisition by United Therapeutics Corporation (NASDAQ:UTHR) for up to $140 million.

Miromatrix Medical climbs 225% following $140m United Therapeutics bid

Miromatrix Medical Inc.'s stock MIRO, -2.80% jumped 230% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp. UTHR, -2.30% for $3.25 per share in cash, or about $91 million. The deal also includes a milestone payment of $1.75 per share in cash upon the achievement of clinical development of Miromatrix's development-stage, fully-implantable manufactured kidney product, Mirokidney by Dec. 31, 2025.

Miromatrix Medical stock soars after it agrees to be bought by United Therapeutics

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. and EDEN PRAIRIE, Minn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix.

United Therapeutics to Acquire Miromatrix Medical.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human cells. United Therapeutics is a biotechnology company with six FDA-approved therapies to address rare, life-threatening condit.

United Therapeutics to Acquire Miromatrix Medical

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its third quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. United Therapeutics will host a public webcast Wednesday, November 1, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast wi.

News for United Therapeutics Stock (UTHR)